Renal Cancer
CEACAM1 gene expression is reduced and reversible in renal cell carcinoma
Published in Cancer Weekly, January 11th, 2005
According to recent research from Germany, "CEACAM1 acts as a tumor suppressor in various epithelial tumors. On the other hand, de novo expression of CEACAM1 is strongly associated with reduced disease-free survival of melanoma and non-small cell lung carcinoma patients. Since effector functions of natural killer and T cells are inhibited by homophilic CEACAM1 interaction, immune escape could be responsible for the poor prognosis of these patients."
"Here, we describe CEACAM1 expression in normal kidney, renal adenomas and renal cell carcinomas (RCC) using a novel antibody...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-01-11)
More Articles from Cancer Weekly
- Breast Cancer
Novel enzyme protects breast tumor cells from oxidative stress - Breast Cancer
Study finds radiation therapy may not be needed after breast cancer surgery - Cancer Genetics
PIK3CA is an oncogene in ovarian cancer, common mutation in early breast cancer - Cancer Immunology
Human body makes antibodies that recognize metastatic breast cancer tumors - Prostate Cancer Therapy
Antibody-chemotherapeutic conjugate designed for prostate cancer therapy - Acute Leukemia Therapy
FLAD regimen shows promise for high-risk patients - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
